Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with TACE for advanced hepatocellular carcinoma
ChiCTR2000031808Phase 4Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hunan Provincial People's Hospital. Primary endpoint: progression-free survival. Started May 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031808.